Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Income from Continuing Operations (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Income from Continuing Operations for 13 consecutive years, with 64002.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations fell 73.74% year-over-year to 64002.0, compared with a TTM value of 298856.0 through Nov 2025, up 33.3%, and an annual FY2025 reading of 313976.0, up 48.21% over the prior year.
  • Income from Continuing Operations was 64002.0 for Q4 2025 at CNBX Pharmaceuticals, up from 129731.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 36837.0 in Q4 2024 and bottomed at 1323775.0 in Q2 2021.
  • Average Income from Continuing Operations over 5 years is 376888.75, with a median of 189755.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations skyrocketed 78.57% in 2024, then crashed 146.95% in 2025.
  • Year by year, Income from Continuing Operations stood at 1110349.0 in 2021, then soared by 68.77% to 346790.0 in 2022, then skyrocketed by 50.43% to 171900.0 in 2023, then surged by 78.57% to 36837.0 in 2024, then tumbled by 73.74% to 64002.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CNBX at 64002.0 in Q4 2025, 129731.0 in Q3 2025, and 40380.0 in Q2 2025.